Big Rock Partners Acquisition News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.03.22	NRx Pharmaceuticals Announces Leadership Transition (PR Newswire)
05.03.22	ROSEN, GLOBAL INVESTOR COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - NRXP; NRXPW (PR Newswire)
18.02.22	Pre-market Movers: NRGV, ROKU, RDFN, CELZ, SHAK… (RTTNews)
15.02.22	NRx Pharmaceuticals Announces US National Institutes of Health Study of ZYESAMI® (aviptadil) in Critical COVID-19 is Cleared to Complete Full Enrollment (PR Newswire)
03.02.22	Pre-market Movers: BON, FB, BPTS, LSPD, SNAP… (RTTNews)
03.02.22	NRx Pharmaceuticals Announces Closing of $25 Million Private Placement Priced at a Premium to Market Under Nasdaq Rules (PR Newswire)
31.01.22	NRx Pharmaceuticals Announces $25 Million Private Placement Priced at a Premium to Market under Nasdaq Rules (PR Newswire)
27.01.22	NRx Announces Publication of Initial Findings of BriLife® Vaccine-produced Antibodies Against Omicron Variant (PR Newswire)
26.01.22	NRx Pharmaceuticals Gets First Safety Report For Its Covid-19 Drug From A Southwestern Hospital (RTTNews)
26.01.22	NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge (PR Newswire)
14.01.22	Relief-Partner NRx wehrt sich gegen Relief-Darstellungen in Rechtsstreit (AWP)
12.01.22	NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics (PR Newswire)
05.01.22	NRx Seeks Emergency Approval For ZYESAMI To Treat Patients At Immediate Risk Of Death From COVID-19 (RTTNews)
05.01.22	NRx Pharmaceuticals Submits Emergency Use Authorization Application to US Food and Drug Administration for ZYESAMI® (aviptadil) to Treat Patients at Immediate Risk of Death from COVID-19 Despite T... (PR Newswire)
03.01.22	NRx Files Provisional Patent For Stable Compositions Of Aviptadil Suitable For Human Use (RTTNews)
03.01.22	NRx Pharmaceuticals Files Provisional Patent for Stable Compositions of Aviptadil Suitable for Human Use (PR Newswire)
29.12.21	NRx Pharma Files Breakthrough Therapy Designation Request For ZYESAMI (RTTNews)
29.12.21	NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approve... (PR Newswire)
22.11.21	Pre-market Movers: ASTR, VG, CEI, CMBM, PTNR… (RTTNews)
05.11.21	NRx Pharmaceuticals Initiates Senior Level Finance and Business Initiatives with Luxembourg Ministry of the Economy, BNP Paribas, and Vaccine Manufacturing Partners for BriLife® COVID-19 Vaccine P... (PR Newswire)
05.11.21	Pre-market Movers: RWLK, OTRK, EVAX, NRXP, PTON… (RTTNews)
04.11.21	US Food and Drug Administration Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure (PR Newswire)
03.11.21	Pre-market Movers: BBBY, RRD, GKOS, TMBR, IRTC… (RTTNews)
02.11.21	NRx Pharmaceuticals Announces Favorable, New Safety Report for ZYESAMI® (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19 (PR Newswire)
15.10.21	Relief-Partner NRx publiziert Daten zu Corona-Therapie in Fachjournal - Relief-Aktie tiefrot (AWP) Der US-Partner von Relief Therapeutics hat in dem Fachjournal "Journal of Infectious Diseases and Treatment" positive Studiendaten der Corona-Therapie Aviptadil veröffentlicht.» mehr
14.10.21	Journal of Infectious Diseases and Treatment Publishes Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure (PR Newswire)
13.10.21	Pre-market Movers: WTRH, NEW, RGLS, KOSS, PROC… (RTTNews)
12.10.21	NRx Pharmaceuticals Announces Progress on Worldwide Commercial Scale Development of ZYESAMI™ (aviptadil) (PR Newswire)
07.10.21	Pre-market Movers: CYRN, CEI, OSMT, NURO, TTM… (RTTNews)
29.09.21	NRx Pharma: Data Safety Monitoring Board Finds No New Safety Concerns In ACTIV-3b Trial (RTTNews)
29.09.21	NRx Pharmaceuticals Announces Second Favorable Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19 (PR Newswire)
27.09.21	NRx Pharmaceuticals Announces Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMI (aviptadil) (PR Newswire)
08.09.21	NRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
07.09.21	Pre-market Movers: IRNT, MTL, IFRX, FWP, JAGX, IPHA… (RTTNews)
30.08.21	Relief-Partner NRx hofft auf "Breakthrough"-Status für Covid-Behandlung - Relief-Aktie im Plus (AWP) Der Relief Therapeutics-Partner NRx Pharmaceuticals strebt für seinen Wirkstoff Aviptadil bei der FDA den Status Therapiedurchbruch (Breakthrough Therapy Designation) an.» mehr
30.08.21	NRx : Zyesami Phase 2b/3 Trial Result Shows Relief From Respiratory Distress In Critical COVID-19 (RTTNews)
30.08.21	NRx Pharmaceuticals Announces New Finding from ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19 (PR Newswire)
26.08.21	NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies (PR Newswire)
24.08.21	NRx Pharmaceuticals Announces Closing of $30 Million Private Placement (PR Newswire)
23.08.21	Participants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary (PR Newswire)
19.08.21	NRx Pharmaceuticals Announces $30 Million Private Placement (PR Newswire)
18.08.21	NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19 (PR Newswire)
17.08.21	NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update (PR Newswire)
10.08.21	NRx Pharmaceuticals to Ring Nasdaq Closing Bell on August 10, 2021 (PR Newswire)
09.08.21	NRx Pharmaceuticals Announces Initiation of Phase 2b Trial of BriLife™ Vaccine for Covid-19 in Nation of Georgia (PR Newswire)
04.08.21	MannKind Partners With NRx Pharma To Explore Dry Powder Formulation Of ZYESAMI (RTTNews)
04.08.21	NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions (PR Newswire)
04.08.21	MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform (PR Newswire)
27.07.21	NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia (PR Newswire)
23.07.21	Relief-Aktie springt letztendlich zweistellig hoch: COVID-19-Medikament Aviptadil kann kommerziell produziert werden (AWP) Das Medikament Aviptadil, das schwere Verläufe von COVID-19 verhindern soll, von Relief Therapeutics kann produziert werden.» mehr

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	592.20	2.28 %	K V
Logitech Intl	90.72	2.00 %	K V
Roche Hldg G	285.50	1.67 %	K V
Geberit	514.00	1.62 %	K V
Alcon	84.02	1.42 %	K V
UBS Group	32.42	0.06 %	K V
Swiss Re	140.15	-0.07 %	K V
Zurich Insur Gr	556.60	-0.36 %	K V
Swisscom	516.50	-0.48 %	K V
ABB	50.04	-2.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Big Rock Partners Acquisition Corp Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten